C11orf53 Inhibitors
These inhibitors operate by disrupting specific cellular pathways that could logically affect the functional activity of C11orf53. For example, Wortmannin and LY294002 target the PI3K/AKT pathway, which is implicated in a wide array of cellular functions including growth, proliferation, and survival. If C11orf53 is an effector in this pathway, inhibition by these compounds could suppress its activity. Similarly, PD98059 and SB431542 inhibit the MAPK/ERK and TGF-β signaling pathways, respectively; both are critical pathways for cell differentiation, growth, and apoptosis. Inhibition of these pathways could logically lead to reduced C11orf53 activity if it is a downstream effector.
Compounds like Y-27632 and Bortezomib affect the cytoskeleton integrity and protein turnover, respectively. If C11orf53's activity requires interaction with the cytoskeleton or is regulated by ubiquitination and proteasomal degradation, these inhibitors could modulate its activity. Torin 1 and Dorsomorphin target mTOR and BMP signaling, which are involved in cellular growth and development.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor that can prevent AKT phosphorylation. If C11orf53 activity is dependent on PI3K/AKT pathway activation, Wortmannin would impede this signaling cascade, potentially reducing C11orf53 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A MEK inhibitor that blocks the MAPK/ERK pathway. If C11orf53 is activated by ERK or part of this signaling cascade, inhibition by PD98059 would reduce its functional activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
An inhibitor of the TGF-β type I receptor ALK5 kinase activity, which can lead to reduced SMAD phosphorylation. If C11orf53 activity is mediated through a TGF-β/SMAD-dependent mechanism, this compound would inhibit its functional activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that impedes actin cytoskeleton organization. If C11orf53 is involved in cell motility or morphology changes dependent on the ROCK pathway, Y-27632 would inhibit these processes and thus C11orf53 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If C11orf53 is regulated by proteasomal degradation, Bortezomib could increase its cellular levels, potentially leading to a negative feedback loop that inhibits its function. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
An mTOR inhibitor that can downregulate protein synthesis and cell growth signals. If C11orf53 is involved in these pathways, its functional activity could be reduced due to a decrease in associated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK signaling. If C11orf53 is activated by JNK or is involved in stress response pathways regulated by JNK, inhibition by SP600125 would reduce its activity. | ||||||
CKI-7 dihydrochloride | 1177141-67-1 | sc-252621 sc-252621A | 5 mg 10 mg | $280.00 $320.00 | 5 | |
A casein kinase I inhibitor, which may affect Wnt signaling and other cellular processes. If C11orf53 is regulated by casein kinase I, its activity would be diminished by CKI-7. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A broad PI3K inhibitor. If C11orf53 functions downstream of the PI3K pathway or is regulated by it, LY294002 would lead to reduced activity of C11orf53. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
An inhibitor of BMP signaling by targeting ALK2, ALK3, and ALK6. If C11orf53 is modulated by BMP signals, this compound would inhibit its functional activity. | ||||||